Movalis (Meloxicam)

Meloxicam works by preferentially inhibiting the cyclooxygenase‑2 (COX‑2) enzyme, which reduces the synthesis of prostaglandins—chemical mediators that promote inflammation, pain, and fever. By lowering prostaglandin levels, meloxicam diminishes inflammatory responses and alleviates pain.

The appropriate dose of Movalis is determined by the prescribing clinician based on the patient’s condition, severity of symptoms, and individual health factors. Dosage decisions are made by qualified healthcare providers and are not standardized across all patients.

The safety of meloxicam during pregnancy or lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Movalis (meloxicam) offers preferential COX‑2 inhibition, which may provide a lower risk of gastrointestinal irritation compared with non‑selective NSAIDs such as ibuprofen or diclofenac. However, individual response and safety profiles vary, and the choice of NSAID should be guided by clinical judgment and patient‑specific factors.

Movalis injectable solution should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Maintain the product in its original packaging until use to preserve stability.

Movalis is administered by a qualified healthcare professional as an intramuscular injection. The injection site and technique follow standard clinical practice to ensure proper absorption and minimize local reactions.

Serious risks include gastrointestinal ulceration or bleeding, severe skin reactions such as Stevens‑Johnson syndrome, renal impairment, hepatic dysfunction, cardiovascular thrombotic events, and anaphylaxis. Patients should be monitored closely for any signs of these conditions.

Movalis should be avoided in individuals with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal ulceration or bleeding, severe renal or hepatic impairment, and patients with established cardiovascular disease unless specifically advised by a physician.